Lutris
Developer of therapeutic drugs designed to improve anti-cancer therapy. The company's drug paves the way for the administration of epidermal growth factor receptor (EGFR) inhibitors to patients withou...
Valuation
$57.1M
Market implied
Share Price
N/A
Total Raised
$38.7M
Last Round
N/A